{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-122784","form_type":"8-K","ticker":"KALV","cik":"0001348911","company_name":"KalVista Pharmaceuticals, Inc.","filed_at":"2026-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.900641+00:00","generated_at":"2026-05-15T08:58:47.130691+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"KalVista reports $49.1M EKTERLY revenue in 8mo transition period, 1,702 patient start forms","bullets":["Global net product revenue of $49.1M from EKTERLY (sebetralstat) for May–Dec 2025; first commercial sales since launch on July 7, 2025.","1,702 patient start forms received in US through Feb 2026, nearly 20% of HAE population; 724 unique prescribers activated.","R&D expenses $33.4M (down from $52.2M YoY); SG&A $124.7M (up from $64.9M) due to commercialization costs.","Cash, equivalents and marketable securities $300.2M as of Dec 31, 2025; company expects to fund through profitability.","Pediatric Phase 3 KONFIDENT-KID trial fully enrolled; interim data to be presented at 2026 Global Angioedema Summit; NDA filing planned Q3 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-122784","json":"https://secwatch.observer/filing/0001193125-26-122784.json","markdown":"https://secwatch.observer/filing/0001193125-26-122784.md","text":"https://secwatch.observer/filing/0001193125-26-122784.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348911/000119312526122784/0001193125-26-122784-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348911/000119312526122784/d127514d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:58:47.130691+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}